English
English
English
Scientists engineer a common gut bacterium into a cancer-fighting tool that targets pancreatic tumours
Chicago: Scientists have developed a new experimental cancer-fighting strategy by transforming a common gut bacterium into a microscopic treatment factory that can enter pancreatic tumours and activate the body’s immune response. The breakthrough has created fresh hope in the battle against one of the deadliest cancers, though human trials are still awaited.
Pancreatic cancer has remained one of the biggest challenges in oncology because of its aggressive nature, late detection and ability to hide from the immune system. Now, researchers are exploring whether engineered bacteria could become a new weapon to target tumours from within.
Scientists at the University of Chicago have modified Bifidobacterium longum, a naturally occurring gut bacterium, into a specialised biological tool designed to reach pancreatic tumours and produce immune-boosting molecules directly inside cancer tissue.
The experimental therapy, called BifidoSumIL-2, showed promising results in animal studies by slowing tumour growth and improving the effectiveness of existing treatments such as chemotherapy, radiation therapy and immunotherapy.
However, researchers have stressed that the technology is still in the early research stage and cannot yet be considered a treatment option for cancer patients.
The idea behind the research is based on a new approach in medicine called synthetic biology, where scientists redesign living organisms to perform specific health-related functions. Researchers engineered Bifidobacterium longum to produce SumIL-2, a modified version of interleukin-2 (IL-2), a protein that plays a key role in activating immune cells.
The engineered bacteria are designed to work like tiny drug factories inside the tumour. Instead of sending medicines throughout the entire body, the bacteria carry the ability to produce the therapeutic molecule directly at the cancer site. Scientists believe this targeted delivery method could potentially increase treatment effectiveness while reducing harmful effects on healthy tissues.
Pancreatic cancer is among the most difficult cancers to treat because tumours create a protective environment that weakens the immune system’s ability to attack. Unlike some other cancers that respond well to immunotherapy, pancreatic tumours often prevent immune cells from reaching and destroying cancer cells.
These tumours are frequently described as “immune cold”, meaning they show limited immune activity despite the presence of cancer-fighting cells in the body. Researchers are trying to change this situation by using engineered bacteria to stimulate immune responses directly inside the tumour environment.
The biggest advantage of using Bifidobacterium longum comes from its natural ability to survive in low-oxygen environments. Many solid tumours contain oxygen-starved areas known as hypoxic regions. These areas are difficult for normal cells but provide suitable conditions for certain bacteria.
Scientists are using this biological weakness of tumours as an advantage. The engineered bacteria are designed to move towards these oxygen-deprived tumour areas, where they can become active and release SumIL-2.
The molecule then helps activate CD8-positive T cells, which are among the body’s strongest cancer-fighting immune cells. The goal is to transform the tumour environment from one that protects cancer into one that allows the immune system to attack it.
Researchers found that the bacterial therapy produced stronger results when combined with existing cancer treatments. In animal studies, combining BifidoSumIL-2 with chemotherapy, radiation therapy and immune checkpoint inhibitors resulted in better tumour control compared with individual treatments.
Scientists believe this combination approach could be important because complex cancers like pancreatic cancer usually require multiple strategies. Chemotherapy can damage cancer cells, radiation can destroy tumour tissue and immunotherapy can remove barriers preventing immune attacks. Engineered bacteria could add another layer by boosting immune activity directly inside the tumour.
The research is part of a growing scientific movement focused on “living medicines” — using specially designed organisms as therapeutic tools. Unlike traditional drugs, engineered bacteria could potentially sense their surroundings, travel to specific disease locations and produce medicines inside the body.
Scientists are investigating similar technologies for cancer treatment, genetic disorders and other complex diseases where targeted drug delivery remains a major challenge. If successful, this approach could redefine precision medicine by turning living organisms into programmable healthcare tools.
Despite the involvement of probiotic bacteria, researchers have warned that ordinary probiotics do not treat pancreatic cancer. The study used a specially engineered bacterial strain created in laboratories with specific cancer-targeting abilities.
Regular yoghurt, probiotic supplements or naturally occurring gut bacteria do not have the same properties and should not be considered alternatives to approved cancer treatments.
While the findings are promising, several questions must be answered before the therapy can reach patients. Scientists need to confirm whether engineered bacteria are safe for humans, whether they can remain limited to tumour areas and whether they can produce consistent results over long periods.
Researchers must also study possible immune reactions, manufacturing challenges and regulatory requirements before moving towards clinical trials. The transition from successful animal experiments to human treatment remains one of the biggest challenges in medical research.
The breakthrough has opened a new direction in cancer research by showing that microorganisms could potentially be redesigned into powerful medical tools. For decades, bacteria were mainly viewed as disease-causing organisms. Advances in biotechnology are now allowing scientists to explore their potential as targeted treatment carriers.
If future studies prove successful, engineered bacteria could become part of a new generation of cancer therapies designed to attack tumours with greater precision. For pancreatic cancer patients, the discovery does not mean an immediate cure, but it represents a significant scientific step towards finding new solutions against a disease that has challenged doctors for decades.
The future of cancer treatment may not only depend on advanced drugs and machines, it could also involve microscopic biological fighters working from inside the tumour itself.
